DALLAS--(BUSINESS WIRE)--Taysha Gene Therapies, Inc., a patient-centric gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system in both rare and large patient populations, today announced the pricing of its initial public offering of 7,869,566shares of common stock at a price to the public of $20.00 per share.

The shares are expected to begin trading on the Nasdaq Global Select Market under the symbol “TSHA” on September 24, 2020, and the offering is expected to close on September 28, 2020, subject to customary closing conditions. In addition, Taysha has granted the underwriters a 30-day option to purchase up to 1,180,434 additional shares of common stock at the initial public offering price less underwriting discounts and commissions.

Goldman Sachs & Co. LLC, Morgan Stanley and Jefferies are acting as joint book-running managers for the offering. Chardan is acting as lead manager for the offering.